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The biological function of short non-coding RNAs known as micro RNAs (miRNAs) is unravelling to uncover a 
complex arrangement within every cell whereby they modulate most cellular responses. There has been much 
investigation as to the influence of miRNA on cell signalling processes and their cellular effects. Moreover, 
recently miRNA have been implicated in both physiological responses, as well as having critical roles in a variety 
of diseased states. The effects of these unique biochemical regulators are often subtle, but decisive with regards 
to a cell’s pathophysiology and disease. Researchers have investigated both the regulation of signalling pathways 
by miRNA, but also the regulation of miRNA generation processes by signalling steps themselves. There exists 
an interesting interrelationship whereby miRNA can reinforce a cell’s signalling effects. Thus miRNA have a 
role in normal cell physiological functioning. Aberrant miRNA generation would therefore lead to unruly 
signalling activity through which disease often results from such dysregulation. We will review the roles for 
miRNA here with emphasis on their function in human leukemia. Better understanding of these mechanisms 
that underlie pathologically-relevant signalling alterations that create cancer or are involved in cancer 
chemotherapy-resistance, will lead to better targeting and treatments for not only leukemia, but all relevant 
cancers. 
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Introduction 
MicroRNA (miRNA) are 20-24 short non-coding RNA 
molecules that bind and repress their target mRNA. The 
pri-miRNA is transcribed in the nucleus by RNA polymerase 
II. The pri-miRNA contains a hairpin structure which is
cleaved off by the enzyme Drosha leaving a 60-70 nucleotide
precursor miRNA (pre-miRNA). The hairpin contain the
mature miRNA sequence. The pre-miRNA undergoes
cytoplasmic translocation by Exportin 5, and is processed by
the Dicer/TRBP complex leaving the mature miRNA.
Traditionally, one strand will incorporate with the 
RNA-induced silencing complex (RISC), thus allowing the 
miRNA to target the 3’UTR of its target mRNA (through 
complementary base paring). High levels of complementary 
base pairing result in double stranded mRNA, causing 
mRNA degradation, while lower levels result in the 
inhibition of the mRNA translation machinery (the primary 
method in humans) [1]. 
Studies have shown miRNA can play an important role in 
most cellular processes including migration, differentiation, 
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apoptosis and proliferation [2]. It is therefore not 
inconceivable that when dysregulated they will be crucial in 
the pathogenesis and disease generation mechanisms. 
miRNAs have already shown to play an important role in 
haematopoiesis (and in physiological processes in general) 
which is highlighted by mice embryos containing Dicer 
knockouts being embryonically lethal, which shows their 
importance and role within organisms[3]. In this review we 
will be looking at the use of miRNA as prognostic tools and 
biomarkers in leukemia. We shall also be discussing their 
importance and function in various leukemia subtypes, plus 
how their understanding and regulation may prove useful in 
combatting diseases such as cancer or its treatment 
resistance. 
Acute Myeloid Leukemia 
Acute Myeloid Leukemia (AML) is a cancerous disease of 
blood cells which is characterised to the excess proliferation 
of myeloid progenitor cells, leading to the accumulation of 
blasts in the bone marrow. AML is a heterogenous disease 
comprising of a variety of genetic disorders (which include 
molecular abnormalities such as FLT3-ITD or WT1 
mutations, and chromosomal abnormalities such as t(11q23) 
or t(8;21). While the majority of AML cases are due to 
chromosomal translocation, a large number are 
cytogenetically normal and are therefore characterised by 
their genetic abnormalities. Common mutations include 
nucleophosmin 1 (NPM1), CCAAT/enhancer binding protein 
alpha (CEBPA), runt- related transcription factor 1 
(RUNX1),  and fms-related tyrosine kinase 3 (FLT3)[4]. 
MiRNA expression patterns have been shown to 
successfully discriminate between different subtypes of 
leukemia. One study used a genome-wide miRNA expression 
profile between acute lymphocytic leukemia (ALL) and 
AML, and identified 27 different miRNAs that displayed 
significant differential expression between these two disease 
subtypes. The most significant being miR-28a/b which had 
low expression, along with the miRNAs let7-b and miR-223 
which were overexpressed in AML compared to ALL. 
Furthermore, these four miRNAs alone were adequate to 
accurately distinguish between AML and ALL, allowing 
them to be considered almost as biomarkers between these 
human leukemic disease subtypes [5].  
Studies have identified miRNA alterations in AML 
(compared to control cells) and between a range of AML 
subtypes. One study investigated miRNA expression in 29 
primary AML samples containing a range of common 
abnormalities [6]. They found each AML subtype had its own 
individual miRNA profile. AML/ETO (a fusion protein 
produced as a result of t(8:21)) for example, caused 
upregulation in 4 miRNA (miR449b, miR-320, miR-126 and 
miR-328) and a concurrent downregulation in 13 miRNAs 
(miR-9, miR-196a, miR-10a, miR-135a, miR-125b, 
miR-148a, miR-133a, and miR-221) compared to the other 
AML subtypes. Another study identified downregulation of 
26 different miRNAs across 122 primary AML patient 
samples (compared to CD34+ control cells) using a miRNA 
microarray-based approach to study the disease. miRNA 
expression was also compared between different AML 
subtypes and compared to the prognosis. As with the 
previous study there was variation in miRNA expression 
dependent on the associated molecular abnormality 
signature. AML with 11q23 translocation was observed to 
have a lower expression of the miRNA, miR-196 [7]. 
miR-196 has previously been implicated in regulating 
HOXB8. The HOXB8 gene can be considered an oncogene 
in AML, whereby is plays a crucial role in preventing 
myeloid differentiation and preventing cellular apoptosis 
through the repression of the pro-apoptotic gene BIM. 
Interestingly, HOXB8 targets BIM through the upregulation 
of the miRNA cluster miR-17-92, The exact mechanisms of 
HOXB8 regulation of miR-17-92 are elusive but are believed 
to be indirect via c-Myc function [8]. miRNA signatures were 
also identified from patients with cytogenetically normal 
AML, where 13 miRNA had lower expression (miR-126, 
miR-203, miR-200c, miR-182, miR-204, miR-196b, 
miR-193, miR-191, miR-199a, miR-194, miR-183, miR-299 
and miR-145) and 10 were upregulated (miR-10a, miR-10b, 
miR-26a, miR-30c, let-7a-2, miR-16-2, miR-21, miR-181b, 
miR368, and miR-192 [7]. Together these studies correlated 
miRNA expression to different subtypes of AML suggesting 
that one day some subtypes of AML could be diagnosed on 
the miRNA pattern alone. 
Moreover, miRNA expression is also a useful marker to 
identify disease progression and prognosis. Garzon et al 
correlated miRNA expression to prognosis they identified 
high expression of miR191 and miR-199a to poor prognosis 
in AML[7]. Another study in CN-AML identified miR-181a 
as another prognostic marker, higher levels of miR-181a was 
a good indication for a less severe prognosis and a lower 
chance of relapse [9]. 
Outside of the microarray studies already discussed, 
several miRNA families have been implicated in AML. 
miR-155 is a known oncomiR, which is a miRNA that 
promotes carcinogenic mechanisms in cells, usually by 
repressing tumor suppressor genes.  The converse of this is 
a tumor suppressor miRNA, which is anti-oncogenic in 
nature by inhibiting expression of cellular oncogenes.  In 
AML, miR-155 is processed from its parent gene 
miR155HG, which is located on chromosome 21 [10]. One 
study identified miR-155 upregulation in subtypes of AML 
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patients (acute myelomonocytic leukemia and acute 
monocytic leukemia, of FAB subtypes M4 and M5), and 
ectopic overexpression in mice resulted in a 
myeloproliferative (pre-leukemic)-like disease. The study 
went on to identify several mRNA targets thought to be 
important in AML, including PU.1, CEBPα and Picalm [11]. 
This is important as PU.1 is an AML tumour suppressor 
thatis mutated in 7% of AML patients (primarily monocytic 
or undifferentiated leukemia) leading to inhibition of 
differentiation [12]. 
As with most miRNA, the role of the miR-125 family is 
tissue-specific, however it has been characterised as an 
oncomiR in leukemia (13). The miR-125 family exists as 
three homologues (miR-125a,b, and c) all on different 
chromosomes. miR-125b exists as two paralogs, miR-125b1 
and miR-125b2 (both contain the same seed region but are 
located on different chromosomes and therefore can be 
regulated independently) [13]. To date miR-125b remains the 
most well characterised member of the miR-125b family in 
leukemia. miR-125b-1 is overexpressed in AML cells, in 
particular patients with the t(2:11)(p21:q23) translocation, 
which showed up to a 90 fold increase in miR-125b-1 levels 
[14]. Ectopic overexpression of miR-125b in mice lead to 
them developing leukemia.  The specific leukemic subtype 
developed was dependent on the level of miR-125b.  
Furthermore, its upregulation is sufficient to shorten the 
latency of the BCR-ABL protein in mice.  While this 
finding on BCR-ABL is less important in the context of 
AML, it helps to highlight miR-125b’s role as an oncomiR in 
blood cancers [15].  
Conversely, miR-29b is a well characterised tumour 
suppressor miRNA in AML. The miR-29 family exists as 
three homologues (miR-29a/b/c) on different 
chromosomes.miR-29b also exists as two paralogs 
(miR-29b1 and miR-29b2). Members of the miR-29 family 
were found to be downregulated in a range of AML samples 
[7], and ectopic overexpression of miR-29b in both primary 
AML samples and in AML cell lines caused their apoptosis. 
Furthermore, when synthetically injected into xenografts, 
their resultant tumour size was reduced, again showing its 
tumour suppressor role [16]. miR-29b targets anti-apoptotic 
genes such as MCL-1, which is itself usually upregulated in 
AML, thus providing one mechanism for miR-29b’s role as a 
tumour suppressor miRNA[16]. 
The transcription factor nuclear factor (erythroid-derived 
2)-like 2 (NRF2) plays an important role in protecting cells 
from reactive oxygen species (ROS). In AML, NRF2 is 
constitutively activated and has shown to play an important 
role in protecting cells from front-line chemotherapeutic 
agents through its regulation of antioxidant genes [17]. Our 
recent study has shown NRF2 can positively regulate 
miR-125b1 and negatively regulate miR-29b1 in both AML 
cell lines and primary patient samples (18). NRF2 regulation 
of miRNA was shown to increase resistance to front-line 
chemotherapy drugs.  This chemo-resistance was nullified 
when these cells were treated with a miR-125b antagomiR 
and miR-29b mimic.  AntagomiRs and miR-mimics are 
short sequence RNAs that can be used as tools to inhibit or 
mimic cellular miRNA functions respectively. Interestingly, 
the most significant increase in sensitivity towards 
chemotherapy was shown when both miRNA were 
simultaneously targeted at the same time, suggesting NRF2 
synergistically regulates both miRNA classes. We believe the 
downstream miRNA pathways that are most likely being 
targeted are AKT2 and BAK1 signalling pathways [18]. 
Chronic Myeloid Leukemia 
Chronic Myeloid Leukemia (CML) disease is caused by 
the excess proliferation of myeloid cells, of a more defined 
cytogenetic profile. CML is primarily characterised by the 
BCR-ABL chromosomal translocation that results in 
uncontrolled proliferation. Briefly, the breakpoint cluster 
region (BCR) on chromosome 22 translocates with the 
Abelson (ABL) tyrosine kinase gene on chromosome 9, 
thereby creating the BCR-ABL fusion gene (known as the 
Philadelphia chromosome).BCR-ABL oncoprotein is also a 
tyrosine kinase with constitutive activity, which drives 
myeloid cellular proliferation as well as repressing apoptosis 
[19]. Unlike AML, CML is a relatively slow developing 
disorder and is characterised by three phases: chronic, 
accelerated and blast crisis. Blast crisis is the final stage of 
CML, where myeloid cells accumulate and cause 
differentiation arrest (more similar in nature to AML). 
Unlike chronic phase CML, once blast crisis has been 
reached patients become unresponsive to chemotherapy 
agents and prognosis is unfavourable.  Before blast crisis, 
Philadelphia chromosome-positive CML, is treated tyrosine 
kinase inhibitors, such as imatinib, nilotinib or dasatinib[19].  
One study by Rokah et al used a miRNA array to 
characterise miRNA expression in CML cell lines and patient 
samples. Several dysregulated miRNAs were identified in 
cell lines. After their further analysis to ensure that the 
dysregulation was CML-specific with confirmation in 
primary patient cells, three miRNA were identified (miR-31, 
miR-155 and miR-564) to be downregulated. After 30 days 
of BCR-ABL inhibition (by imatinib) upregulation was 
observed in all three miRNA indicating BCR-ABL must at 
least partly play a role in repressing these miRNA. Target 
analysis identified several genes that these miRNAs can 
regulate including KRAS, AKT2, E2F3, CBL and cyclin D1. 
These target genes also showed increased expression in 
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CML, suggesting an inverse correlation between the miRNA 
and their targets (as would be expected). All four gene targets 
are well characterised oncogenes thus giving insight into a 
mechanism that would promote a more aggressive CML 
phenotype [20]. 
Another study identified miR-96 upregulation, and 
miR-120, miR-151 and miR-10 downregulation in CML. 
Conversely, miR-10 downregulation was shown to be 
independent to BCR-ABL signalling, the method of miR-10 
inhibition remains elusive, with no evidence of methylation 
or mutation that could be found. USF2 was however 
identified as a downstream target of miR-10, when miR-10 
was overexpressed in CML cells both a decrease in USF2 
and a lack of cell proliferation was found indicating miR-10 
plays an important role in CML [21]. miR-10 is also 
downregulated in most AML subtypes with the exception of 
patients with NPM1 mutations in which it curiously 
overexpressed [22,23]. 
Until relatively recently the prognosis for CML patients 
was poor, with the majority inevitably reaching blast crisis. 
CML treatment has been revolutionised by tyrosine kinase 
inhibitors (TKI) most notably imatinibmesylate (Gleevec), 
which works by inhibiting the BCR-ABL by binding to the 
ATP docking site of its tyrosine kinase motif, thereby 
causing apoptosis in the CML cell expressing the 
Philadelphia chromosome. A small but significant number of 
patients do however suffer from imatinib resistance[24]. One 
study aimed to identify miRNA expression in response to 
imatinib, they found a decrease in (miR-142-3p and 
miR-199b-5p) and an increase in (miR-146a and miR-150) 
[25]. miR-150 for example has shown to be involved in Myb 
regulation (a critical oncogene in CML)[26].miR-146 
upregulation targets members of the NF-κB pathway 
(IRAK1/TRAF6)that are found to be constitutively activated 
in CML by BCR-ABL [27]. Furthermore, inhibiting the 
NF-κB pathway in CML results in apoptosis, suggesting that 
the upregulation of miR-146 post-imatinib treatment makes 
CML cells more sensitive to apoptotic 
signalling[28].miR-199b on the other hand is downregulated 
in response to imatinib treatment. One miR-199b target is 
HES1 (a target of the notch signalling pathway) which 
represses proliferation in meduloblastoma cells [29]. However 
Notch/Hes1 have been implicated in repressing proliferation 
in CML, which indicates miR-199b-5p may be inhibiting 
Hes1 to promote cancer growth in CML [26]. 
As previously mentioned, blast crisis is the most severe 
stage of CML, and despite advances in treatment, even today 
prognosis remains poor. One study identified miR-328 as 
downregulated in blast crisis and when re-expressed causes 
differentiation by restoring CEBPA expression (through 
interacting with hnRNP). Interestingly CEBPA expression 
was able to positively regulate miR-328, thereby indicating 
the existence of a positive feedback loop, thus in CML 
hnRNP represses miR-328 via CEBPA silencing thereby 
aiding the pathogenesis in blast crisis. Conversely miR-328 
does not silence hnRNP but instead prevents it from binding 
to CEBPA protein [30]. 
Acute Lymphocytic Leukemia 
Acute Lymphocytic Leukemia (ALL) is defined by excess 
proliferation of lymphoid progenitor cells from either a B or 
T cell lineage.  Unlike other leukemic subtypes, ALL 
primarily affects children and young adults [31]. One study 
aimed to characterise miRNA expression in the ALL subtype 
pre B-ALL using a combination approach of microarrays, 
qRT-PCR and bioinformatics. miR-451 and miR-373* were 
downregulated, while an increase in miR-222, mIR-339 and 
miR-142-3p was identified in pre-B-ALL cells compared to 
control CD19+[32]. Another study focussing in childhood 
ALL identified dysregulation in several miRNA which 
included an upregulation in the miR-181 family, miR-34, 
miR-193 and a downregulation in miR-196, miR-125b, 
miR-100 [33]. The oncogenic protein c-Myc is a key miR-196 
target, which is upregulated in B-ALL due to t(8;14)(q24;32) 
translocations. In B-ALL miR-196 overexpression results in 
the decreased expression in c-Myc (and its associated genes) 
along with a significant increase in apoptosis [34]. Conversely, 
despite miR-196 being downregulated in T-ALL, it is unable 
to target c-Myc due to a mutation in the 3’UTR of the 
miR-196/c-Myc binding region [35]. miR-196 is located 
between HOXA9 and HOXA10, and has an oncogenic role 
in leukemia patients characterised by a HOXA mutation, 
including mixed-lineage leukemia (MLL) and T-ALL. It is 
also possible to identify between different ALL subtypes 
(B-ALL and T-ALL) using miRNA signatures: miR-151 
(downregulated in T-ALL), miR-148a and miR-424 (both 
highly expressed in T-ALL) could all be used to discriminate 
between these two leukemic subtypes [36]. Furthermore, it is 
possible to distinguish between B-ALL subtypes using 
miRNA expression, as exemplified by miR-629 having high 
expression in MLL-AF4, miR-425-5p miR-191 and miR-128 
being highly expressed in E2A-PBX1. BCR-Abl also 
generates higher expression of miR-146b and miR-126. 
Prognosis can be tested by miRNA expression.  For 
example, miR-223 and miR-27a were upregulated in patients 
who were in ALL remission while miR-708 was upregulated 
in relapsed patients [37]. Target analysis suggested miR-27a 
may be targeting protein BMI-1, which has been implicated 
in survival and self-renewal in leukemic stem cells [38]. It can 
also target MDR1 (multidrug-resistance gene) [39]. Their 
repression by miR-23a would be detrimental to leukemic cell 
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survival. miR-708 will also repress FOXO3 expression, 
which has a dual oncogene/tumour suppressor role in cancer.  
Curiously, this study identified low levels of FOXO3 in 
patients with a high risk of relapse but high levels in patients 
who have actually relapsed [37]. Studies in CML has 
identified FOXO3 as critical for maintaining the leukemic 
initiating cells in that disease, with its removal decreasing the 
ability of leukemic initiating cells [40]. The interaction 
between miR-708 and FOXO3 still remains speculative. 
Chronic Lymphocytic Leukemia 
Chronic Lymphocytic Leukemia (CLL) is the most 
common leukemia subtype worldwide. CLL comes about by 
the excessive proliferation and accumulation of lymphocytes 
in the bone marrow, blood and lymph nodes. CLL is 
characterised usually with abnormal B cell receptor (BCR) 
signalling function.  Briefly, antigen binding to BCR causes 
signal transduction by phosphorylating ITAMs and 
recruitment of SYK tyrosine kinase, which activates Bruton’s 
Tyrosine Kinase (BTK) through PI3K.BTK can activate 
downstream targets such as NF-κB, which is done through 
PLCγ2 activation. Various prognostic markers exist for CLL 
including mutational status of IGHV and expression levels of 
ZAP70. High expression of ZAP70 and/or no mutation in 
IGHV results in a poorer prognosis in patients [41]. 
miRNA expression could be a useful tool for diagnosis in 
CLL.  One study aimed to identify miRNA expression 
between CLL patients and control cells, finding changes in 
expression levels of several miRNA including miR-123, 
miR-10b, miR-181b, miR-192, miR-220, miR-155 and 
miR-213.This study also suggested miRNA can be used to 
distinguish between both IgHv mutations and ZAP70 levels 
[42]. 
Several miRNA have been functionally implicated in 
CLL. miR-15a/16 is a tumour suppressor miRNA that is 
downregulated in CLL[43]. It is located on 13q14.3 (an area 
commonly deleted in CLL as well as various other 
cancers).Using a bioinformatics approach, the mitochondrial 
integrity protein BCL2 has been identified as a miR15a/16 
target, being confirmed via reporter assays [44]. In CLL, 
BCL2 is a well characterised oncogene that represses 
apoptosis in cancer. The luciferase reporter assay used 
showed miR-15a/16 have the ability to inhibit BCL2, and 
when miR-15a/16 is artificially overexpressed a marked 
increase in apoptosis was seen [44]. Conversely, one study 
identified a proportion of CLL cases without 13q14.3 
deletion, yet miR-15a/16 were still poorly expressed [45]. This 
may however be due to HDAC-mediated silencing of the 
miR15a/16 region (along with miR-29b) [46]. 
As in AML, miR-155 is overexpressed in CLL [42], and is 
highly expressed in patients who respond poorly to treatment 
or are unresponsive to fludarabine chemotherapy[47].miR-155 
can be regulated by several proteins including the Myb (an 
oncogene involved in CLL) and Smad4 (a member of the 
TGFβ family) [48,49]. miR-155 can target the tumour 
suppressor PU.1 which in addition to being a key tumour 
suppressor in AML (as discussed above) is additionally 
important in CLL. miR-155 can also target the phosphatase 
SHIP1, which reduces BCR sensitivity.  Indeed, miR-155 
inhibition in CLL resulted in a decreased sensitivity in BCR 
ligation, thus providing an interesting relationship between 
miR-155 and BCR. Furthermore, this study identified 
miR-155 as upregulated in the lymph nodes of CLL patients, 
but down-regulated when the CLL lymphocytes egress into 
the bloodstream [50]. 
Conclusions 
In summary, we have highlighted a broad network of 
miRNA expression in human leukemia. Some have 
oncogenic activity while others a have tumor suppressive 
role. What needs to be explored next is whether we have the 
technology to target these dysregulated miRNA in a clinical 
disease setting such as leukemia. Alternatively, if this is an 
unworkable strategy we could use the expression profiling to 
inform the clinic on diagnosis and prognosis of the disease, 
or maybe allow for more targeted chemotherapy treatment.  
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